Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 761

The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.

Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Open access
Dickinson, Michael J., Carlo-Stella, Carmelo, Morschhauser, Franck, Bachy, Emmanuel, Corradini, Paolo, Iacoboni, Gloria, Khan, Cyrus, Wróbel, Tomasz, Offner, Fritz, Trněný, Marek, Wu, Shang-Ju, Cartron, Guillaume, Hertzberg, Mark, Sureda, Anna, Perez-Callejo, David, Lundberg, Linda, Relf, James, Dixon, Mark, Clark, Emma, Humphrey, Kathryn, Hutchings, Martin·2022·New England Journal of Medicine

Abstract

BACKGROUND: The prognosis for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) is poor. Glofitamab is a bispecific antibody that recruits T cells to tumor cells. METHODS: In the phase 2 part of a phase 1-2 study, we enrolled patients with relapsed or refractory DLBCL who had received at least two lines of therapy previously. Patients received pretreatment with obinutuzumab to mitigate cytokine release syndrome, followed by fixed-duration glofitamab monotherapy (12 cycles total). The primary end point was complete response according to assessment by an independent review committee. Key secondary end points included duration of response, survival, and safety. RESULTS: Of the 155 patients who were enrolled, 154 received at least one dose of any study treatment (obinutuzumab or glofitamab). At a median follow-up of 12.6 months, 39% (95% confidence interval [CI], 32 to 48) of the patients had a complete response according to independent review. Results were consistent among the 52 patients who had previously received chimeric antigen receptor T-cell therapy (35% of whom had a complete response). The median time to a complete response was 42 days (95% CI, 42 to 44). The majority (78%) of complete responses were ongoing at 12 months. The 12-month progression-free survival was 37% (95% CI, 28 to 46). Discontinuation of glofitamab due to adverse events occurred in 9% of the patients. The most common adverse event was cytokine release syndrome (in 63% of the patients). Adverse events of grade 3 or higher occurred in 62% of the patients, with grade 3 or higher cytokine release syndrome in 4% and grade 3 or higher neurologic events in 3%. CONCLUSIONS: Glofitamab therapy was effective for DLBCL. More than half the patients had an adverse event of grade 3 or 4. (Funded by F. Hoffmann-La Roche; ClinicalTrials.gov number, NCT03075696.).

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa2206913

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 26 references

Research works printed but not linked: 4

  1. 10.2217/fon-2020-0522 · doi:10.2217/fon-2020-0522
  2. 10.1007/s40265-016-0650-8 · doi:10.1007/s40265-016-0650-8
  3. Guidetti A Perrone G Coluccia P et al. The real life accessibility to CAR T-cell therapy: current experience in the only active center in Italy. 2019;134:Suppl 1:5619-5619. abstract. · doi:10.1182/blood-2019-125286
  4. Kuhnl A, Roddie C, Tholouli E, et al. Real-world data of high-grade lymphoma patients treated with CD19 CAR-T in the UK. Br J Haematol 2020;189:30-31. abstract.

Cited by

See all 761

Metadata

Authors
Dickinson, M. J., Carlo-Stella, C., Morschhauser, F., Bachy, E., Corradini, P., Iacoboni, G., Khan, C., Wróbel, T., Offner, F., Trněný, M., Wu, S.-J., Cartron, G., Hertzberg, M., Sureda, A., Perez-Callejo, D., Lundberg, L., Relf, J., Dixon, M., Clark, E., Humphrey, K., & Hutchings, M.
Venue
New England Journal of Medicine
Published
2022-12-15
Volume
387
Issue
24
Pages
2220-2231
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W4311537867
Cited by
761
References
26
FWCI
81.31
Type
journal article
Language
en
Open access
bronze
Funders
F. Hoffmann-La Roche

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma. https://app.cochat.ai/papers/10.1056/nejmoa2206913
The paper
Dickinson, M. J., Carlo-Stella, C., Morschhauser, F., Bachy, E., Corradini, P., Iacoboni, G., Khan, C., Wróbel, T., Offner, F., Trněný, M., Wu, S.-J., Cartron, G., Hertzberg, M., Sureda, A., Perez-Callejo, D., Lundberg, L., Relf, J., Dixon, M., Clark, E., . . . Hutchings, M. (2022). Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2206913

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.